• Site Search
  • News
  • Product
  • Zhejiang Medical Technology Development Co., Ltd.

    2019 year
    26 day
    Winhealth Group signed a contract CDCO model getting on track

     1. Strategically working with NASDAQ listed pharmaceutical enterprise

    On April 26, 2019, Mr. Wang Wei, president of Hongkong Winhealth Pharma Group Co., Ltd , and Mr. A.J. Kazimi, CEO of Cumberland Pharmaceuticals (NASDAQ: CPIX), signed a strategic cooperation agreement in Nashville, Tennessee. The two sides will carry out all-round cooperation in product import, research and development registration, incubation financing, etc.

    Winhealth Group signed a contract  CDCO model getting on track 

    On the same day, the two sides also signed an exclusive commercial license agreement for Ibuprofen Injection and other products in the Chinese market, covering full-cycle, integrated and customized services such as product registration, market access, large-scale commercialization, localized production and product life cycle management. Winhealth Group will also take a strategic stake in the New Technology Incubation Center (CET), which is invested by Cumberland Pharmaceuticals, Vanderbilt University (its School of Medicine ranking the top 10 in the United States) and the Tennessee government, and be dedicated to the research, development and incubation of new products and technologies in the medical field, and cooperation with relevant medical colleges and scientific research institutions in China.

    Winhealth Group signed a contract  CDCO model getting on track


    About Cumberland Pharmaceuticals

    Cumberland Pharmaceuticals is a professional pharmaceutical company listed on NASDAQ. It is responsible for purchasing, developing and commercializing famous prescription drugs, and aims to improve the quality of medical care and solve unmet medical needs.

    2. Successful cooperation in microsphere project in Germany 

    On April 28, Mr. Wang went to Berlin in person to discuss the long-term strategic cooperation between Winhealth and PharmaCept with Mr. Dr.Ebert, CEO of PharmaCept, and reached an agreement on exclusive cooperation in the Chinese market. Winhealth will obtain the exclusive market rights of its core product EmboCept® series in China, and is responsible for the registration access, large-scale commercialization and channel management of products in China.

    The EmboCept® series biodegradable microspheres are the fist products of PharmaCept, which have been applied in Europe for ten years. It plays an important role in the field of transcatheter arterial chemoembolization (TACE) for primary liver cancer (HCC) and metastatic liver cancer. Compared with traditional lipiodol and drug eluting microspheres, the EmboCept® series products have the characteristics of repeated embolization and significant reduction of side effects such as pain and vomiting. More importantly, due to its short-term degradability, the elevation of local vascular endothelial growth factor (VEGF) can be avoided, thus overcoming the disadvantages in establishment of tumor tissue collateral circulation in traditional interventional embolization. The efficacy and safety of the EmboCept® series products have been confirmed in a large number of clinical studies and animal experiments.

    Winhealth Group signed a contract  CDCO model getting on track 


    For the vast liver cancer market in China, PharmaCept hopes to work with Winhealth to jointly develop the market for the benefit of more Chinese liver cancer patients.

    As a leading CDCO company in China, Hongkong Winhealth Pharma Group Co., Ltd will focus on the Chinese market so as to allow global high-quality new special drugs to access into China faster and more efficiently and to be commercialized for the benefit of hundreds of millions of patients. These three times of cooperation are consistent with Winhealth's CDCO positioning and further enrich Winhealth's future product line.

    In the future, we hope to carry out long-term cooperation with more excellent pharmaceutical enterprises, introduce more innovative products and advanced therapy to jointly develop the market, and make positive contributions to promoting the progress of China's health cause and improving the quality of human life.

    3rd Floor, Winhealth Industrial Park, No. 272 Huancheng East Road, Xiacheng District, Hangzhou, Zhejiang, China
    BD@winhealth.Hk (overseas)
    0571-8718 6358    4008393773 ( Product Hotline )
    Copyright ©2019 - 2024 Zhejiang Medical Technology Development Co., Ltd.